Exelixis, Inc., is a biotechnology company engaged in the development of small molecule therapies for cancer. The Company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc., in November 1994 and changed to Exelixis, Inc., in February 2000. The company has launched four marketed drugs, including two formulations of its flagship molecule cabozantinib. Exelixis is actively advancing its product line, and its lead clinical candidate, zanzatinib, is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of colorectal cancer (CRC). The company also has a large late-stage clinical development program aimed at developing other indications. With a rational and rigorous investment strategy, Exelixis leverages its internal expertise and strong strategic partnerships to identify and seize opportunities in various scientific fields including small molecule drugs and biological therapies such as antibody-drug conjugates (ADCs).
